Literature DB >> 7967988

Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer.

P Lewis1, S Griffin, P Marsden, T Gee, T Nunan, M Malsey, J Dussek.   

Abstract

Despite use of computed tomography, some lung cancer patients are found to have unresectable disease at surgery, or they present early with metastases. We studied whether whole-body positron emission tomography (PET) with 18F-fluorodeoxyglucose (18FDG) would improve the preoperative detection of metastases. We retrospectively analysed 34 patients with "operable" non-small-cell lung cancer who underwent 18FDG PET after routine assessment. Management changes produced by the PET scan and confirmatory tests were reviewed. PET identified unsuspected malignant lesions in 10 (29%) patients. Management changes occurred in 14 (41%), including 6 (18%) patients who were changed to non-surgical therapy. These data suggest that whole-body 18FDG PET improves preoperative assessment of lung cancer patients.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7967988     DOI： 10.1016/s0140-6736(94)90753-6

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


  23 in total

1.  Requirements for clinical PET: comparisons within Europe.

Authors:  Michael Bedford; Michael N Maisey
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-02       Impact factor: 9.236

Review 2.  18F-fluorodeoxyglucose PET scans in lung cancer.

Authors:  J M Hughes
Journal:  Thorax       Date:  1996-08       Impact factor: 9.139

Review 3.  Positron emission tomography/computerized tomography in lung cancer.

Authors:  Ilgin Sahiner; Gulin Ucmak Vural
Journal:  Quant Imaging Med Surg       Date:  2014-06

Review 4.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

5.  Staging of non-small-cell lung cancer by whole-body fluorine-18 deoxyglucose positron emission tomography.

Authors:  T Bury; A Dowlati; P Paulus; R Hustinx; M Radermecker; P Rigo
Journal:  Eur J Nucl Med       Date:  1996-02

6.  Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).

Authors:  A Guhlmann; M Storck; J Kotzerke; F Moog; L Sunder-Plassmann; S N Reske
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

7.  Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver?

Authors:  Markus Selzner; Thomas F Hany; Peer Wildbrett; Lucas McCormack; Zakiyah Kadry; Pierre-Alain Clavien
Journal:  Ann Surg       Date:  2004-12       Impact factor: 12.969

Review 8.  Current role of positron emission tomography in thoracic oncology.

Authors:  V J Lowe; K S Naunheim
Journal:  Thorax       Date:  1998-08       Impact factor: 9.139

9.  Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: prospects for detection and management.

Authors:  C B Wilson; H E Young; R J Ott; M A Flower; B F Cronin; B E Pratt; V R McCready; A Horwich
Journal:  Eur J Nucl Med       Date:  1995-06

10.  Positron emission tomography in the management of lung cancer.

Authors:  Vahid Reza Dabbagh Kakhki
Journal:  Ann Thorac Med       Date:  2007-04       Impact factor: 2.219
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.